What the Opioid Epidemic Costs Employers
The opioid epidemic in the U.S. cost employers $2.6 billion in 2016 to pay in treatment costs covered by insurance plans.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 140
Conatus Pharmaceuticals Stumbles on Midstage Miss
Conatus Pharmaceuticals shares took a big step back on Thursday after the firm announced that its midstage proof-of-concept clinical trial in liver transplant patients with fibrosis or cirrhosis failed to live up to expectations.
Proteostasis Therapeutics Wins Big With FDA Decision
Proteostasis Therapeutics shares made a solid gain on Wednesday after a key FDA decision was announced.
Celgene Shuffles the Deck: COO Steps Down Immediately
Celgene is shuffling the deck in terms of its executive leadership, and one of its top executives is stepping down.
Rigel Pharmaceuticals Stumbles on Midstage Kidney Trial
Rigel Pharmaceuticals saw its shares pull back early on Tuesday after the firm announced topline data from a midstage study.
Pfizer’s Late-Stage Win Not Enough to Offset Monday Market Carnage
Pfizer shares took a small step back on Monday despite announcing positive results from a late-stage trial. The pullback seems to be the product of overall market sentiment as opposed to these results.
FDA Gets Down on Alkermes Depression Drug
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Major Biopharma Catalysts, Conferences and Decisions to Watch For in April
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Question for Coffee Industry: Does Beverage Cause Cancer?
A California judge ruled that one ingredient in coffee was dangerous enough to be a potential cause of cancer. The judge made his decision on a limited amount of information.
What a Buyout Could Mean for Shire
Shares of Shire saw a solid gain on Wednesday after the firm announced that it received an offer to be acquired by Takeda Pharmaceutical.
Why Edge Therapeutics Fell Off the Edge of the Earth
Edge Therapeutics saw its shares plunge massively following the results from a late-stage trial.
Can Arrowhead Pharma Keep Up the Pace?
Arrowhead Pharmaceuticals shares made a solid gain on Tuesday after the company gave an update on its midstage study of ARO-HBV in the treatment of patients with chronic hepatitis B virus infection.
Major Biotechs See Rising Tide in Short Interest
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Which Major Pharma Stocks Short Sellers Are Keen On
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Why ImmunoGen Could See Another 60% of Potential Upside
ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology annual meeting.